Article Details

TLSA: Nasally-administered Foralumab Trial in SPMS Patient

Retrieved on: 2021-05-27 15:11:15

Tags for this article:

Click the tags to see associated articles and topics

TLSA: Nasally-administered Foralumab Trial in SPMS Patient. View article details on hiswai:

Excerpt

The meeting was called to discuss potential merits of teplizumab, which, like foralumab, is an anti-CD3 monoclonal antibody (mAb). In contrast to ...

Article found on: news.yahoo.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up